2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2759

The Risk of Ischaemic Stroke in Primary APS Patients: A Prospective Study
Abstract Number: 2760

Antiphospholipid Syndrome Alliance for Clinical Trials & International Networking (APS ACTION) Clinical Database and Repository (“Registry”) Analysis: First and Recurrent Thrombosis Risk after 1201 Patient-Years of Follow-up
Abstract Number: 2761

Adenosine Receptor Agonism Protects Against Antiphospholipid Antibody-Mediated Netosis and Venous Thrombosis
Abstract Number: 2762

Study of 60 Patients with Intrauterine Fetal Deaths Related to Antiphospholipid Syndrome
Abstract Number: 2763

mTORC1 Blockade with Rapamycin and N-Acetylcysteine Reduces Anti-Phospholipid Antibody Levels in Controlled Clinical Trials of Patients with SLE
Abstract Number: 2764

Gene Expression Profile in Monocytes of Antiphospholipid Syndrome Patients Reveals Novel Altered Genes and Pathways Involved in the Pathophysiology of the Disease
Abstract Number: 2765

Centre of Pressure Characteristics during Walking in Individuals with and without First Metatarsophalangeal Joint Osteoarthritis
Abstract Number: 2766

Physical Therapy Vs. Internet-Based Exercise Training for Patients with Knee Osteoarthritis: Results of a Randomized Controlled Trial
Abstract Number: 2767

Active Yet Sedentary: The Association of Moderate to Vigorous Physical Activity and Sedentary Behavior with Incident Functional Limitation in Knee OA
Abstract Number: 2768

Effects of a Home-Based Telephone-Supported Physical Activity Program on Physical Function Among Older Adults with Chronic Low Back Pain
Abstract Number: 2769

Predictive Value of Leisure-Time Physical Activity in Women with Systemic Erythematosus Lupus on Physical and Mental Health
Abstract Number: 2770

Using Fitbits. Fitabase®, and Remote Coaching to Increase Physical Activity in Employees with Knee Osteoarthritis Symptoms
Abstract Number: 2771

NOMID-Associated Complications in Mice Are Prevented By CDD-450, a Small Molecule Inhibitor of the Mitogen-Activated Protein Kinase-Activated Protein Kinase 2 (MK2) Pathway
Abstract Number: 2772

Unbound IL-18 Distinguishes Human Macrophage Activation Syndrome from Familial Hemophagocytic Lymphohistiocytosis and Affects Innate Versus Adaptive Murine Lymphocytes Differently
Abstract Number: 2773

Severe Juvenile Arthritis Associated with a De Novo Gain-of-Function Germline Mutation in MYD88

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].